Annual Drug Patent Expirations for SAXENDA
Saxenda is a drug marketed by Novo and is included in one NDA. It is available from two suppliers. There are twenty-three patents protecting this drug.
Drug patent litigation for SAXENDA.
This drug has thirty-eight patent family members in thirteen countries.
The generic ingredient in SAXENDA is liraglutide recombinant. Two suppliers are listed for this compound. Additional details are available on the liraglutide recombinant profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
